Mechanism & research context
Tirzepatide is a synthetic 39-amino-acid peptide that activates both the GIP and GLP-1 incretin receptors. In preclinical and in-vitro models it is studied for receptor crosstalk, cAMP signalling, insulin-secretion kinetics and adipocyte metabolism. Supplied as lyophilized powder at ≥98% HPLC purity.
Selected studies
"Tirzepatide, a dual GIP / GLP-1 receptor agonist, achieved up to 20.9% body-weight reduction at 72 weeks — substantially exceeding outcomes for single-receptor incretin therapies."
New England Journal of Medicine — SURMOUNT-1 trialView study
Use disclaimerFor Research Use Only. Not for Human Consumption. Not a drug, food, or cosmetic.
Article reflects published preclinical and in-vitro literature..